The risk factors for and presentation of Candida tropicalis fungemia, in comparison with those of Candida albicans, have been incompletely characterized. We compared 43 cases of C. tropicalis fungemia with 148 cases of C. albicans fungemia. In univariate analysis, patients with C. tropicalis fungemia were more likely to have leukemia ( ), prolonged neutropenia ( ), and a positive blood culture for more days ( P p .0006 P p .03 P p ). The 2 groups did not differ with regard to baseline Acute Physiology and Chronic Health Evaluation .02 (APACHE) II score, frequency of catheter-associated fungemia, or response to antifungals. In multivariate analysis, patients with C. tropicalis fungemia were more likely to have leukemia ( ), previous neutropenia P p .02 ( ), and a longer stay in the intensive care unit during the infectious episode ( ). Also, the P p .002 P p .01 response of the breakthrough C. tropicalis fungemia was lower ( ). In conclusion, the host determinants P p .05 associated with susceptibility to C. tropicalis are leukemia and prolonged neutropenia.
bution of C. tropicalis as a pathogen in patients with cancer at high risk for fungemia and contrast it with that of C. albicans. To that end, we conducted this retrospective study, which covered a 6-year period, to identify the risk factors and other relevant prognostic data associated with C. tropicalis fungemia in patients with cancer, and we compared the findings with those associated with C. albicans fungemia in the same population.
PATIENTS AND METHODS
We identified 43 consecutive patients with cancer who experienced C. tropicalis fungemia from 1 January 1993 through 31 December 1998 in the microbiology records of The University of Texas M.D. Anderson Cancer Center (Houston). The 43 patients were compared with 148 patients with cancer in whom C. albicans fungemia developed during the study period. Patients with mixed fungemia were excluded from both cohorts. A case of C. tropicalis fungemia was defined as one that had у1 blood culture positive for C. tropicalis in the presence of signs and symptoms of systemic infection. In addition, the patients' medical records were reviewed for the following demographic and potential risk factors: age; sex; underlying disease; Acute Physiology and Chronic Health Evaluation (APACHE) II score on the day of the first positive blood culture; duration of hospitalization; duration of intensive care unit (ICU) stay; and receipt of steroids, total body irradiation, chemotherapy, cyclosporin A, tacrolimus, iv hyperalimentation, or prophylactic antifungals; and presence of neutropenia. These clinical characteristics were noted within 30 days of occurrence of the first positive blood culture and during the course of 1 infection. Neutropenia was defined as a neutrophil count of !500 cells/mm 3 at the time of onset of infection. Finally, "response to antifungal treatment" was defined as the resolution of all clinical manifestations of fungemia with blood cultures negative for C. tropicalis, and "failure" was defined as persistence of the clinical signs and symptoms of the fungal infection in the absence of an intercurrent infection, blood cultures positive for C. tropicalis, or both.
For categorical data, we used Fisher's exact text when we compared C. tropicalis fungemia cohorts with C. albicans cohorts and evaluated the response of C. tropicalis fungemia to antifungals. For numerical data, we used Student's t test and the Wilcoxon rank sum test. Also, we used logistic regression with a stepwise backward elimination to determine multiple discriminators between C. tropicalis and C. albicans and predictors of response by C. tropicalis. Significance was assigned for P values of р.05, and no adjustments were made for multiple comparisons. All analyses were performed using SAS software (STAT, version 8; SAS Institute).
RESULTS
Many (44%) of the 43 patients with C. tropicalis fungemia had hematologic malignancy as an underlying disease (table 1) . In contrast, the majority of patients who had C. albicans fungemia (76%) had an underlying solid tumor ( ). Neutropenia P p .02 before or at the onset of fungemia was much more common in the cohort of patients who had C. tropicalis fungemia (60% vs. 26%;
). Also, the mean duration of neutropenia P p .0004 was longer in this group (6 days vs. 2 days;
). Similarly, P p .03 more patients with C. tropicalis fungemia remained neutropenic during their infection ( ) and were given growth P p .00009 factors ( ) or WBC transfusions during their infection P p .007 ( ). Finally, more patients with C. tropicalis fungemia P p .01 had received systemic antifungals either empirically or prophylactically within 30 days before entry into the study (26% vs. 16%;
). The 2 patient groups did not differ in other P p .18 characteristics, such as baseline APACHE II score, response to antifungals, or frequency of central venous catheters, including catheter-related fungemia (data not shown).
The presence of leukemia and neutropenia before the first positive blood culture was an independent risk factor for the occurrence of C. tropicalis fungemia in multivariate analysis (table 2). Most (53%) of the 43 patients with C. tropicalis fungemia had a positive blood culture on more than 1 day. Ten (44%) of those 23 patients had fungemia for 15 days. All but 2 of those 10 patients with persistent C. tropicalis fungemia were treated with fluconazole (400 mg/d). In addition, the duration of ICU stay tended to be longer during the infectious episode in patients with C. tropicalis fungemia (OR, 3.1; 95% CI, 1.2-7.7;
; table 2). P p .017 The treatment failure rate was higher in patients with persistent neutropenia (55%) than it was in those without neutropenia or those who had recovered from neutropenia (P p ; table 3). Also, the treatment failure rate was higher in .047 patients who had leukemia and myelodysplastic syndrome (53%) than it was in those who did not (  ; table 3 ). P p 0.012 Persistent neutropenia was the only independent factor for poor outcome of C. tropicalis fungemia in multivariate analysis (OR, 6.9; 95% CI, 1.6-29.7;
). On the other hand, the ma-P p .01 jority (88%) of patients with C. tropicalis fungemia who had a solid tumor as underlying disease had a response to antifungal treatment (table 3) .
Most of the patients with C. tropicalis fungemia (39 [91%] of 43) received therapeutic antifungals (amphotericin B deoxycholate, lipid formulations of amphotericin B, or fluconazole) at some time during the treatment of their infection (table 1) . Clinical and microbiologic response of the infection to the antifungals was observed in 27 (69%) of the 39 treated patients. Eleven (73%) of the 15 patients with breakthrough C. tropicalis fungemia had underlying leukemia. However, only 6 (14%) of 43 patients developed breakthrough C. tropicalis fungemia if they had previously received fluconazole prophylaxis. The response rate to fluconazole in patients with C. tropicalis fungemia who had not previously received prophylaxis with fluconazole was comparable with that to treatment with amphotericin B or with lipid formulations of amphotericin B. However, when C. tropicalis fungemia represented a breakthrough infection despite previous prophylactic or empiric antifungal treatment, the response rate was lower compared with C. tropicalis fungemia representing a de novo infection (table 4) .
Eleven percent of all the fungemia cases that occurred during the study period were caused by C. tropicalis, making C. tropicalis the fifth most common bloodstream Candida isolate after C. albicans (34%), Candida glabrata (19%), Candida parapsilosis (18%), and Candida krusei (12%). The incidence of C. tropicalis fungemia has remained stable, going from 0.6 cases per 1000 hospital admissions in 1993 to 0.8 cases per 1000 hospital admissions in 1998 ( ). P p NS
DISCUSSION
This study reports what is to our knowledge the largest recent series of patients with cancer with C. tropicalis fungemia at a single institution. We found that C. tropicalis fungemia remains a significant cause of fungemia in patients with hematologic malignancies because almost half of the patients had a hematologic malignancy (mainly leukemia) as an underlying disease. Similarly, neutropenia was found in the majority (60%) of cases of C. tropicalis fungemia. In fact, as shown in table 2, leukemia and neutropenia, were, according to multivariate analysis, independent factors favoring C. tropicalis fungemia, as has been reported elsewhere [1] [2] [3] [4] [7] [8] [9] . In contrast to other studies that have reported the frequent occurrence of C. tropicalis fungemia in critically ill patients with high APACHE II scores [4] , in our study, patients with both C. tropicalis and C. albicans fungemia had similarly low severity scores of illness at the onset of their infections (table 1) . However, in comparison with patients who had C. albicans fungemia, those who had C. tropicalis fungemia were more likely to have had persistent fungemia and a longer ICU stay during the course of their infection. This may signify a higher virulence of C. tropicalis when compared with C. albicans in the setting of neutropenia, as has been suggested in other studies [1, 3, 4, 7] . For example, the high pathogenicity of C. tropicalis was illustrated by the observation that as many as 60%-80% of colonized patients with neutropenia eventually develop invasive infection [1, 10] . However, whether C. tropicalis does indeed have higher virulence is debatable. C. tropicalis is not more virulent than is C. albicans when introduced into the bloodstream in animal models [1, 11, 12] . However, C. tropicalis was more virulent than was C. albicans when introduced in the gastrointestinal tract in the setting of neutropenia and mucositis in animals [13] [14] [15] . Those results suggest that C. tropicalis does not have higher virulence but, rather, that it takes advantage of the host.
In addition, our study showed that persistent neutropenia is a strong prognostic factor for poor response. Previous riskstratification models of candidemia in patients with cancer have described the poor prognostic significance of the presence of leukemia, neutropenia, or a high baseline APACHE II score [2, 4, 7, 9, 16] . We failed to identify the severity of illness score as a prognostic factor, perhaps because of the relatively small number of C. tropicalis fungemia episodes and because the affected patients had relatively low baseline APACHE II scores.
Our antifungal therapy response data should be viewed with caution because decisions about management were not controlled. The limited data comparing fluconazole with amphotericin B in patients with C. tropicalis fungemia suggest that both agents are comparable, at least in stable patients or those lacking neutropenia [17] . Nevertheless, our data support the notion that breakthrough C. tropicalis fungemia in this patient population is associated with suboptimal efficacy of subsequent antifungal therapy. In contrast, others have suggested that this may not be true if one controls for other severity measures of infection, such as the APACHE II score [18] . However, such an analysis was not feasible because of the small number of breakthrough fungemia cases.
Only a minority of the cases of C. tropicalis fungemia in our study developed in the setting of fluconazole prophylaxis. There have been conflicting reports regarding whether there has been an emergence of resistance of this Candida species to fluconazole, because cases of breakthrough fluconazole-resistant C. tropicalis fungemia in patients receiving fluconazole have been reported [8, 19, 20] . C. tropicalis has been shown to rapidly acquire a stable, broad spectrum of resistance to azoles after exposure to increasing concentrations of fluconazole in vitro through upregulation of efflux transporters [21] . However, recent population-based surveillance studies of candidemia have suggested that C. tropicalis has negligible level of fluconazole resistance [22] [23] [24] .
Finally, our data demonstrated that although the rate of C. tropicalis fungemia remained constant, its relative frequency has been continuously decreasing in our institution since 1990 [4] . More specifically, when compared with the period of 1988-1992, in which fluconazole use at the M.D. Anderson Cancer Center was not widespread, C. tropicalis shifted from the second to the fifth leading cause of fungemia. This trend also coincided with the emergence of other non-albicans Candida species resistant to fluconazole, both in our institution and elsewhere [4, 8, [22] [23] [24] [25] . In fact, absence of fluconazole prophylaxis was shown to be an independent predictor of C. tropicalis fungemia in this patient population in an earlier study at our institution [4] . We did not find such an association in our study, most likely because we used neutropenia as the first independent variable in regression analysis. Therefore, because the majority of patients with prolonged neutropenia were receiving prophylactic or empiric antifungals at the onset of their C. tropicalis fungemia, the independent contribution of the lack of use of antifungals, especially that of fluconazole, could not be demonstrated. Nevertheless, the contribution of fluconazole use to the changing epidemiology of fungemia has been questioned by some researchers [26] .
Our study has several limitations as a result of its retrospective nature that did not allow an assessment of other, potentially important differences between the 2 cohorts, such as the presence of mucositis, myositis, type and duration of previous or concomitant antibacterials, dissemination, and underlying disease activity. In addition, our study did not look at types of invasive C. tropicalis infection other than fungemia, such as meningitis; C. tropicalis is the leading cause of Candida meningitis in children with cancer [27] . Finally, we did not provide data concerning C. tropicalis-attributable mortality. Some studies [5, 28] -but not all [7, 9, 29] -have suggested that C. tropicalis sepsis results in a higher mortality rate in this patient population.
In summary, C. tropicalis, even though it is less common than are other Candida species, remains an important pathogen, especially in patients with neutropenia who have hematologic malignancies, including those patients who are receiving fluconazole. There are distinct differences in presentation and risk factors between C. tropicalis and C. albicans fungemia. Poor prognostic factors for the outcome of C. tropicalis fungemia are having leukemia, persistent neutropenia, and, possibly, breakthrough fungemia.
